Report Detail
Global (United States, European Union and China) Alzheimer's Disease Therapeutics and Diagnostics Market Research Report 2019-2025
- RnM3675396 |
- 16 August, 2019 |
- Global |
- 117 Pages |
- QYResearch |
- Pharma & Healthcare
Alzheimer’s disease (AD) is the most common reason of progressive dementia in the elderly population. There has been an exponential rise in the number of cases of Alzheimer’s disease worldwide emphasizing the necessity for developing an effective treatment. According to Alzheimer’s Association, in 2016, an estimated 5.4 million Americans of all ages have Alzheimer's disease. One in nine people aged 65 and above has Alzheimer's disease. By 2050, the number of people aged 65 and above affected with Alzheimer's disease is expected to nearly triple, from 5.2 million to an expected 13.8 million, excluding the development of medical advances to avert or cure the disease. The mortality rates due to Alzheimer’s disease are quite high. Between 2000 and 2013, deaths due to heart disease, stroke and prostate cancer decreased 14%, 23% and 11%, respectively, while deaths from AD increased 71% in the U.S. Similarly, According to Alzheimer’s disease International in 2015, there are an estimated 46.8 million people worldwide living with dementia and is further expected to grow in future. Thus, there is an increasing in the demand for Alzheimer’s therapeutics and diagnostics worldwide.
Population aging across the globe is a major factor driving the market for Alzheimer’s therapeutics and diagnostics. Rising life expectancy is contributing to quick increases in number of aged population, and is associated with increased prevalence of chronic diseases like dementia. Therapies for AD offer temporary and uncertain improvements in the well-being of individuals, and none of the approved drugs can modify the course of the disease advancement. Thus, the magnitude of the affected population and lack of suitable and effective treatment offers an incredible opportunity for drug manufacturers. However, identification of the primary reasons and mechanisms involved in AD are is limited. Drug manufacturers have been unable to validate significant clinical benefits of treatment for a numerous of new compounds due to strict regulations. One of the significant trend observed in this market is collaboration of the existing players. Precisely, diagnostic technology companies are carefully trying to bring about effective biomarker technologies to support and improve the drug development process for potential drug candidates which is further expected to propel the demand.
In 2019, the market size of Alzheimer's Disease Therapeutics and Diagnostics is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Alzheimer's Disease Therapeutics and Diagnostics.
This report studies the global market size of Alzheimer's Disease Therapeutics and Diagnostics, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Alzheimer's Disease Therapeutics and Diagnostics sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
Namenda
Aricept
Exelon
Solanezumab
Gantenerumab
Verubecestat
Pfizer
Eisai
Actavis
Lundbeck
Daiichi Sankyo
Novartis
TauRx
Market Segment by Product Type
Biomarkers
Cholinesterase inhibitors
NMDA receptor antagonists
Brain imaging
Blood tests
Market Segment by Application
Drugs Market
Diagnostics Market
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Alzheimer's Disease Therapeutics and Diagnostics status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Alzheimer's Disease Therapeutics and Diagnostics manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Alzheimer's Disease Therapeutics and Diagnostics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Major Manufacturers Covered in This Report
- 1.3 Market Segment by Type
- 1.3.1 Global Alzheimer's Disease Therapeutics and Diagnostics Market Size Growth Rate by Type (2019-2025)
- 1.3.2 Biomarkers
- 1.3.3 Cholinesterase inhibitors
- 1.3.4 NMDA receptor antagonists
- 1.3.5 Brain imaging
- 1.3.6 Blood tests
- 1.4 Market Segment by Application
- 1.4.1 Global Alzheimer's Disease Therapeutics and Diagnostics Market Share by Application (2019-2025)
- 1.4.2 Drugs Market
- 1.4.3 Diagnostics Market
- 1.5 Study Objectives
- 1.6 Years Considered
2 Global Growth Trends
- 2.1 Global Alzheimer's Disease Therapeutics and Diagnostics Market Size
- 2.1.1 Global Alzheimer's Disease Therapeutics and Diagnostics Revenue 2014-2025
- 2.1.2 Global Alzheimer's Disease Therapeutics and Diagnostics Sales 2014-2025
- 2.2 Alzheimer's Disease Therapeutics and Diagnostics Growth Rate by Regions
- 2.2.1 Global Alzheimer's Disease Therapeutics and Diagnostics Sales by Regions 2014-2019
- 2.2.2 Global Alzheimer's Disease Therapeutics and Diagnostics Revenue by Regions 2014-2019
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
3 Market Share by Manufacturers
- 3.1 Alzheimer's Disease Therapeutics and Diagnostics Sales by Manufacturers
- 3.1.1 Alzheimer's Disease Therapeutics and Diagnostics Sales by Manufacturers 2014-2019
- 3.1.2 Alzheimer's Disease Therapeutics and Diagnostics Sales Market Share by Manufacturers 2014-2019
- 3.2 Revenue by Manufacturers
- 3.2.1 Alzheimer's Disease Therapeutics and Diagnostics Revenue by Manufacturers (2014-2019)
- 3.2.2 Alzheimer's Disease Therapeutics and Diagnostics Revenue Share by Manufacturers (2014-2019)
- 3.2.3 Global Alzheimer's Disease Therapeutics and Diagnostics Market Concentration Ratio (CR5 and HHI)
- 3.3 Alzheimer's Disease Therapeutics and Diagnostics Price by Manufacturers
- 3.4 Key Manufacturers Alzheimer's Disease Therapeutics and Diagnostics Plants/Factories Distribution and Area Served
- 3.5 Date of Key Manufacturers Enter into Alzheimer's Disease Therapeutics and Diagnostics Market
- 3.6 Key Manufacturers Alzheimer's Disease Therapeutics and Diagnostics Product Offered
- 3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
- 4.1 Sales and Revenue for Each Type
- 4.1.1 Biomarkers Sales and Revenue (2014-2019)
- 4.1.2 Cholinesterase inhibitors Sales and Revenue (2014-2019)
- 4.1.3 NMDA receptor antagonists Sales and Revenue (2014-2019)
- 4.1.4 Brain imaging Sales and Revenue (2014-2019)
- 4.1.5 Blood tests Sales and Revenue (2014-2019)
- 4.2 Global Alzheimer's Disease Therapeutics and Diagnostics Sales Market Share by Type
- 4.3 Global Alzheimer's Disease Therapeutics and Diagnostics Revenue Market Share by Type
- 4.4 Alzheimer's Disease Therapeutics and Diagnostics Price by Type
5 Market Size by Application
- 5.1 Overview
- 5.2 Global Alzheimer's Disease Therapeutics and Diagnostics Sales by Application
6 United States
- 6.1 United States Alzheimer's Disease Therapeutics and Diagnostics Breakdown Data by Company
- 6.2 United States Alzheimer's Disease Therapeutics and Diagnostics Breakdown Data by Type
- 6.3 United States Alzheimer's Disease Therapeutics and Diagnostics Breakdown Data by Application
7 European Union
- 7.1 European Union Alzheimer's Disease Therapeutics and Diagnostics Breakdown Data by Company
- 7.2 European Union Alzheimer's Disease Therapeutics and Diagnostics Breakdown Data by Type
- 7.3 European Union Alzheimer's Disease Therapeutics and Diagnostics Breakdown Data by Application
8 China
- 8.1 China Alzheimer's Disease Therapeutics and Diagnostics Breakdown Data by Company
- 8.2 China Alzheimer's Disease Therapeutics and Diagnostics Breakdown Data by Type
- 8.3 China Alzheimer's Disease Therapeutics and Diagnostics Breakdown Data by Application
9 Rest of World
- 9.1 Rest of World Alzheimer's Disease Therapeutics and Diagnostics Breakdown Data by Company
- 9.2 Rest of World Alzheimer's Disease Therapeutics and Diagnostics Breakdown Data by Type
- 9.3 Rest of World Alzheimer's Disease Therapeutics and Diagnostics Breakdown Data by Application
- 9.4 Rest of World Alzheimer's Disease Therapeutics and Diagnostics Breakdown Data by Countries
- 9.4.1 Rest of World Alzheimer's Disease Therapeutics and Diagnostics Sales by Countries
- 9.4.2 Rest of World Alzheimer's Disease Therapeutics and Diagnostics Revenue by Countries
- 9.4.3 Japan
- 9.4.4 Korea
- 9.4.5 India
- 9.4.6 Southeast Asia
10 Company Profiles
- 10.1 Namenda
- 10.1.1 Namenda Company Details
- 10.1.2 Company Description and Business Overview
- 10.1.3 Sales, Revenue and Market Share of Alzheimer's Disease Therapeutics and Diagnostics
- 10.1.4 Alzheimer's Disease Therapeutics and Diagnostics Product Introduction
- 10.1.5 Namenda Recent Development
- 10.2 Aricept
- 10.2.1 Aricept Company Details
- 10.2.2 Company Description and Business Overview
- 10.2.3 Sales, Revenue and Market Share of Alzheimer's Disease Therapeutics and Diagnostics
- 10.2.4 Alzheimer's Disease Therapeutics and Diagnostics Product Introduction
- 10.2.5 Aricept Recent Development
- 10.3 Exelon
- 10.3.1 Exelon Company Details
- 10.3.2 Company Description and Business Overview
- 10.3.3 Sales, Revenue and Market Share of Alzheimer's Disease Therapeutics and Diagnostics
- 10.3.4 Alzheimer's Disease Therapeutics and Diagnostics Product Introduction
- 10.3.5 Exelon Recent Development
- 10.4 Solanezumab
- 10.4.1 Solanezumab Company Details
- 10.4.2 Company Description and Business Overview
- 10.4.3 Sales, Revenue and Market Share of Alzheimer's Disease Therapeutics and Diagnostics
- 10.4.4 Alzheimer's Disease Therapeutics and Diagnostics Product Introduction
- 10.4.5 Solanezumab Recent Development
- 10.5 Gantenerumab
- 10.5.1 Gantenerumab Company Details
- 10.5.2 Company Description and Business Overview
- 10.5.3 Sales, Revenue and Market Share of Alzheimer's Disease Therapeutics and Diagnostics
- 10.5.4 Alzheimer's Disease Therapeutics and Diagnostics Product Introduction
- 10.5.5 Gantenerumab Recent Development
- 10.6 Verubecestat
- 10.6.1 Verubecestat Company Details
- 10.6.2 Company Description and Business Overview
- 10.6.3 Sales, Revenue and Market Share of Alzheimer's Disease Therapeutics and Diagnostics
- 10.6.4 Alzheimer's Disease Therapeutics and Diagnostics Product Introduction
- 10.6.5 Verubecestat Recent Development
- 10.7 Pfizer
- 10.7.1 Pfizer Company Details
- 10.7.2 Company Description and Business Overview
- 10.7.3 Sales, Revenue and Market Share of Alzheimer's Disease Therapeutics and Diagnostics
- 10.7.4 Alzheimer's Disease Therapeutics and Diagnostics Product Introduction
- 10.7.5 Pfizer Recent Development
- 10.8 Eisai
- 10.8.1 Eisai Company Details
- 10.8.2 Company Description and Business Overview
- 10.8.3 Sales, Revenue and Market Share of Alzheimer's Disease Therapeutics and Diagnostics
- 10.8.4 Alzheimer's Disease Therapeutics and Diagnostics Product Introduction
- 10.8.5 Eisai Recent Development
- 10.9 Actavis
- 10.9.1 Actavis Company Details
- 10.9.2 Company Description and Business Overview
- 10.9.3 Sales, Revenue and Market Share of Alzheimer's Disease Therapeutics and Diagnostics
- 10.9.4 Alzheimer's Disease Therapeutics and Diagnostics Product Introduction
- 10.9.5 Actavis Recent Development
- 10.10 Lundbeck
- 10.10.1 Lundbeck Company Details
- 10.10.2 Company Description and Business Overview
- 10.10.3 Sales, Revenue and Market Share of Alzheimer's Disease Therapeutics and Diagnostics
- 10.10.4 Alzheimer's Disease Therapeutics and Diagnostics Product Introduction
- 10.10.5 Lundbeck Recent Development
- 10.11 Daiichi Sankyo
- 10.12 Novartis
- 10.13 TauRx
11 Value Chain and Sales Channels Analysis
- 11.1 Value Chain Analysis
- 11.2 Sales Channels Analysis
- 11.2.1 Alzheimer's Disease Therapeutics and Diagnostics Sales Channels
- 11.2.2 Alzheimer's Disease Therapeutics and Diagnostics Distributors
- 11.3 Alzheimer's Disease Therapeutics and Diagnostics Customers
12 Market Forecast
- 12.1 Global Alzheimer's Disease Therapeutics and Diagnostics Sales and Revenue Forecast 2019-2025
- 12.2 Global Alzheimer's Disease Therapeutics and Diagnostics Sales Forecast by Type
- 12.3 Global Alzheimer's Disease Therapeutics and Diagnostics Sales Forecast by Application
- 12.4 Alzheimer's Disease Therapeutics and Diagnostics Forecast by Regions
- 12.4.1 Global Alzheimer's Disease Therapeutics and Diagnostics Sales Forecast by Regions 2019-2025
- 12.4.2 Global Alzheimer's Disease Therapeutics and Diagnostics Revenue Forecast by Regions 2019-2025
- 12.5 United States Market Forecast
- 12.6 European Union Market Forecast
- 12.7 China Market Forecast
- 12.8 Rest of World
- 12.8.1 Japan
- 12.8.2 Korea
- 12.8.3 India
13 Research Findings and Conclusion
14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.1.1 Research Programs/Design
- 14.1.1.2 Market Size Estimation
- 14.1.1.3 Market Breakdown and Data Triangulation
- 14.1.2 Data Source
- 14.1.2.1 Secondary Sources
- 14.1.2.2 Primary Sources
- 14.1.1 Methodology/Research Approach
- 14.2 Author Details
Summary:
Get latest Market Research Reports on Alzheimer's Disease Therapeutics and Diagnostics. Industry analysis & Market Report on Alzheimer's Disease Therapeutics and Diagnostics is a syndicated market report, published as Global (United States, European Union and China) Alzheimer's Disease Therapeutics and Diagnostics Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Alzheimer's Disease Therapeutics and Diagnostics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
